CardioSignal wins ACC.22 Future Hub Innovation Pitch Challenge in Washington D.C.
CardioSignal, a health technology company developing motion sensor technology to improve heart disease detection, was announced a winner in the Innovation Pitch Challenge by American College of Cardiology's Annual Scientific Session & Expo 2022 in Washington D.C. on April 3, 2022. The Pitch Challenge was organized in partnership with the National Heart Lung and Blood Institute (NHLBI).
American College of Cardiology (ACC) is a global gathering of thousands of cardiovascular professionals where practice-changing science and innovations are presented and discussed.
CardioSignal presented the capabilities of a unique motion sensor technology for the detection of heart disease such as atrial fibrillation, heart failure and coronary artery disease. In front of the live Future Hub audience, the pitch was followed by a 5-minute Q&A from an expert panel.
“Digitalization and new virtual care solutions have the potential to change the course of cardiovascular disease detection and help with the constantly increasing disease and cost burden. I want to thank the ACC organizers for shedding light on emerging technologies that will bring lifesaving detection tools more accessible to people,” said Tero-Pekka Alastalo, MD, PhD, CardioSignal’s Pitch Challenge presenter and the CMO and the General Manager for US operations.
“CardioSignal is building a digital cardiac biomarker that can revolutionize scalable remote patient monitoring and earlier detection of heart disease. Our plan is to launch this technology in the United States this year,” said CEO, cardiologist Juuso Blomster.
CardioSignal’s key messages at ACC 2022:
The problem:
The prevalence, mortality and costs of cardiovascular disease are growing
Delays in diagnostics are leading to worse outcomes and higher costs
There is a lack of accessible, scalable, and efficient technologies for telemedicine and primary care services
Growing racial and income disparity amplifies the burden
The solution:
Motion sensor technology enables digital biomarkers for early detection of major heart diseases, such as atrial fibrillation, heart failure and coronary artery disease – accessible with just a smartphone (no other devices needed)
This innovation is built on 10+ years of academic research, with excellent performance in clinical validations
CardioSignal is building the next-generation digital cardiovascular screening, monitoring and diagnostics platform and launching the technology in the United States during 2022
For further details, visit: www.cardiosignal.com and www.acc.org.
Contact:
Tero-Pekka Alastalo, tpa@cardiosignal.com
Juulia Simonen (Communications) juulia.simonen@cardiosignal.com, tel. +358503059018
About CardioSignal
We develop groundbreaking medical device solutions for the detection of heart diseases. Our unique patented motion sensor technology enables effective and accessible digital biomarkers for major heart diseases. Originally an academic spinoff, the company’s technology is built on a decade of research and algorithm development. CardioSignal is a brand and a product by Precordior. www.cardiosignal.com
